A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1478 participants.
Also called NCT05610280
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,478 participants
- Sponsor
- Registry
-
NCT05610280 -
2022-501486-53
-
- Other papers using this trial's data
- Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study
- Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Canada, Czechia, Denmark, France, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05610280. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-21 (actual); primary completion 2024-08-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Condition
- Cardiovascular Diseases
- Condition
- Atherosclerosis
- Intervention (Drug)
- Olezarsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05610280- Content hash
5cfeb6a725fc083e98cb0b4502386efcb84fe30ee3a2918521e0138588ed082c